CN112351773A - 包含他克莫司的缓释药物制剂 - Google Patents

包含他克莫司的缓释药物制剂 Download PDF

Info

Publication number
CN112351773A
CN112351773A CN201980038619.2A CN201980038619A CN112351773A CN 112351773 A CN112351773 A CN 112351773A CN 201980038619 A CN201980038619 A CN 201980038619A CN 112351773 A CN112351773 A CN 112351773A
Authority
CN
China
Prior art keywords
tacrolimus
sustained
disintegrant
release pharmaceutical
pharmaceutical preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980038619.2A
Other languages
English (en)
Chinese (zh)
Inventor
金珉永
金暋洙
朴信政
林宗来
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chong Kun Dang Corp
Original Assignee
Chong Kun Dang Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chong Kun Dang Corp filed Critical Chong Kun Dang Corp
Publication of CN112351773A publication Critical patent/CN112351773A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201980038619.2A 2018-06-22 2019-06-20 包含他克莫司的缓释药物制剂 Pending CN112351773A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2018-0071811 2018-06-22
KR1020180071811A KR102081176B1 (ko) 2018-06-22 2018-06-22 타크로리무스를 포함하는 서방형 약제학적 제제
PCT/KR2019/007460 WO2019245309A1 (en) 2018-06-22 2019-06-20 A sustained release pharmaceutical preparation comprising tacrolimus

Publications (1)

Publication Number Publication Date
CN112351773A true CN112351773A (zh) 2021-02-09

Family

ID=68983011

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980038619.2A Pending CN112351773A (zh) 2018-06-22 2019-06-20 包含他克莫司的缓释药物制剂

Country Status (5)

Country Link
JP (2) JP2021526559A (ja)
KR (1) KR102081176B1 (ja)
CN (1) CN112351773A (ja)
TW (1) TWI762789B (ja)
WO (1) WO2019245309A1 (ja)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115944630A (zh) * 2023-02-06 2023-04-11 华北制药股份有限公司 一种他克莫司缓释制剂及其制备方法
CN116159034A (zh) * 2023-04-23 2023-05-26 国药集团川抗制药有限公司 一种他克莫司缓释胶囊及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1301157A (zh) * 1998-03-26 2001-06-27 藤泽药品工业株式会社 延释制剂
CN108379235A (zh) * 2018-06-01 2018-08-10 杭州中美华东制药有限公司 能够快速崩解的他克莫司缓释片剂组合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080181947A1 (en) * 2006-09-26 2008-07-31 Astellas Pharma Inc. Controlled release dosage form of tacrolimus
CA2674039A1 (en) * 2006-12-28 2008-07-17 Astellas Pharma Inc. Sustained release formulation for tacrolimus
KR101714090B1 (ko) * 2008-07-08 2017-03-08 벨로시스 파마슈티컬스 에이/에스 이식 환자의 개선된 치료를 위한 타크로리무스

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1301157A (zh) * 1998-03-26 2001-06-27 藤泽药品工业株式会社 延释制剂
CN108379235A (zh) * 2018-06-01 2018-08-10 杭州中美华东制药有限公司 能够快速崩解的他克莫司缓释片剂组合物

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115944630A (zh) * 2023-02-06 2023-04-11 华北制药股份有限公司 一种他克莫司缓释制剂及其制备方法
CN115944630B (zh) * 2023-02-06 2024-04-05 华北制药股份有限公司 一种他克莫司缓释制剂及其制备方法
CN116159034A (zh) * 2023-04-23 2023-05-26 国药集团川抗制药有限公司 一种他克莫司缓释胶囊及其制备方法

Also Published As

Publication number Publication date
JP2021526559A (ja) 2021-10-07
KR20200000038A (ko) 2020-01-02
TW202015663A (zh) 2020-05-01
WO2019245309A1 (en) 2019-12-26
KR102081176B1 (ko) 2020-02-25
JP2022162149A (ja) 2022-10-21
TWI762789B (zh) 2022-05-01
JP7470161B2 (ja) 2024-04-17

Similar Documents

Publication Publication Date Title
JP7470161B2 (ja) タクロリムスを含む徐放性薬剤学的製剤
KR20090016611A (ko) 메만틴의 약학 조성물
AU2014299447B2 (en) Pharmaceutical capsule composite formulation comprising tadalafil and tamsulosin
WO2004054574A1 (ja) 経口固形医薬
JPH06234635A (ja) インターロイキン１ベータを阻害するためのレフルノミドの使用
US20230190732A1 (en) Pharmaceutical composition containing nitroxoline prodrug, and preparation method and application therefor
US10660963B2 (en) Pharmaceutical composition containing tacrolimus and preparation methods thereof
KR20190010578A (ko) 새로운 다파글리플로진 결정형 및 그의 제조 방법 및 용도
AU2021351536A1 (en) Pharmaceutical formulations for treating diseases mediated by kdm1a
KR20090086686A (ko) 용출율이 개선된 실리마린 함유 약학적 조성물 및 이의제조방법
CN114126712A (zh) 无定形司巴森坦（sparsentan）组合物
EP2593089B1 (en) Solid dispersion of alfa-ketoamide derivative
CN111565714B (zh) 包含依维莫司的实现稳定化的药剂学制剂
AU2007258325B2 (en) Pharmaceutical formulations and compositions of a selective antagonist of either CXCR2 or both CXCR1 and CXCR2 and methods of using the same for treating inflammatory disorders
CN110833530A (zh) 一种盐酸达泊西汀口崩片及其制备方法和应用
CN101829071B (zh) 一种阿利克仑脂质体片剂
KR102065236B1 (ko) 속방형 덱사메타손 및 서방형 온단세트론을 포함하는 1일 1회 복합 구강 속붕해정 및 이의 제조방법
EP4268816A1 (en) Oral solid preparation
RU2247561C1 (ru) Комбинированная фармацевтическая композиция с противотуберкулёзным действием
WO2023237875A1 (en) Plurality of granules
WO2016135740A1 (en) Process for preparing stable oral compositions of everolimus
RU2203663C1 (ru) Антигистаминный препарат "субрестин"
KR20200084649A (ko) 약학 조성물
CN111683659A (zh) 一种氨基吡喃衍生物的组合物
EA045716B1 (ru) Композиция конденсированных трициклических производных гамма-аминокислоты для лечения и/или предупреждения механической боли и её приготовление

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination